Almac’s Predictive Assay for Anti-Angiogenic Agents
Almac has identified and validated a powerful gene expression biomarker which identifies a molecular subgroup of patients who may benefit from anti-angiogenic therapy following standard of care chemotherapy.
This assay has the potential to be used as a companion diagnostic for anti-angiogenic agents across a range of disease areas.
Almac initially presented the identification of this molecular subgroup at ASCO 2011 and further validation of the signature in the ICON7 clinical trial was presented by Dr. Charlie Gourley from the University of Edinburgh at ASCO 2014: ‘Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab‘.
Additional validation studies are currently being performed in high-grade serous ovarian cancer (HGSOC) as well as in other cancer types.